{"abstract": "The deal with the biotechnology company Adaptimmune comes a little over a month after Glaxo agreed to sell its cancer drug business to the Swiss pharmaceutical maker Novartis.", "web_url": "https://dealbook.nytimes.com/2014/06/02/glaxosmithkline-in-350-million-cancer-drug-venture/", "snippet": "The deal with the biotechnology company Adaptimmune comes a little over a month after Glaxo agreed to sell its cancer drug business to the Swiss pharmaceutical maker Novartis.", "lead_paragraph": "LONDON \u2013 Adaptimmune, a biotechnology company, said on Monday that it had reached a deal that could be worth more than $350 million to develop an early stage cancer drug with the pharmaceutical maker GlaxoSmithKline.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-articleLarge.jpg", "height": 401, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 401}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-jumbo.jpg", "height": 684, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-superJumbo.jpg", "height": 1368, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/06/03/business/dbpix-GlaxoSmithKline/dbpix-GlaxoSmithKline-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "GlaxoSmithKline in $350 Million Cancer Drug Venture", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Biotechnology", "rank": 1, "major": "N"}, {"name": "subject", "value": "Cancer", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 4, "major": "N"}, {"name": "organizations", "value": "GlaxoSmithKline PLC", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Novartis AG", "rank": 6, "major": "N"}, {"name": "glocations", "value": "England", "rank": 7, "major": "N"}], "pub_date": "2014-06-02T09:04:35+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Chad Bray", "person": [{"firstname": "Chad", "middlename": null, "lastname": "Bray", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/7d47d352-eb38-5874-8cc5-ec0ad240c08a", "word_count": 302, "uri": "nyt://article/7d47d352-eb38-5874-8cc5-ec0ad240c08a"}